Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) Stock Competitors & Peer Comparison
See ARQT's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for ARQT and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| ARQT | $26.58 | +9.97% | 3.1B | 116.62 | $0.21 | N/A |
| VRTX | $510.08 | +0.88% | 127.7B | 26.45 | $19.03 | N/A |
| MRNA | $225.00 | +14.52% | 78.2B | -24.17 | -$8.15 | N/A |
| REGN | $746.54 | +0.60% | 76.2B | 16.21 | $45.63 | +0.50% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $825.03 | -11.14% | 50.9B | 29.52 | $27.73 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $189.76 | -5.53% | 40B | -21.33 | -$8.82 | N/A |
| ONC | $354.47 | -2.62% | 37.4B | 61.63 | $5.68 | N/A |
| RVMDW | $9.77 | -9.20% | 37.1B | -1.07 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
ARQT vs VRTX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, VRTX has a market cap of 127.7B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while VRTX trades at $510.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas VRTX's P/E ratio is 26.45. In terms of profitability, ARQT's ROE is +0.15%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, ARQT is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
ARQT vs MRNA Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, MRNA has a market cap of 78.2B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while MRNA trades at $225.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas MRNA's P/E ratio is -24.17. In terms of profitability, ARQT's ROE is +0.15%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, ARQT is less volatile compared to MRNA. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
ARQT vs REGN Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, REGN has a market cap of 76.2B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while REGN trades at $746.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas REGN's P/E ratio is 16.21. In terms of profitability, ARQT's ROE is +0.15%, compared to REGN's ROE of +0.14%. Regarding short-term risk, ARQT is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
ARQT vs VRNA Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas VRNA's P/E ratio is -102.80. In terms of profitability, ARQT's ROE is +0.15%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, ARQT is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
ARQT vs ARGX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, ARGX has a market cap of 50.9B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while ARGX trades at $825.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas ARGX's P/E ratio is 29.52. In terms of profitability, ARQT's ROE is +0.15%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, ARQT is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
ARQT vs SGEN Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas SGEN's P/E ratio is -57.19. In terms of profitability, ARQT's ROE is +0.15%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, ARQT is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
ARQT vs RVMD Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, RVMD has a market cap of 40B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while RVMD trades at $189.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas RVMD's P/E ratio is -21.33. In terms of profitability, ARQT's ROE is +0.15%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, ARQT is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
ARQT vs ONC Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, ONC has a market cap of 37.4B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while ONC trades at $354.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas ONC's P/E ratio is 61.63. In terms of profitability, ARQT's ROE is +0.15%, compared to ONC's ROE of +0.14%. Regarding short-term risk, ARQT is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ONC's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
ARQT vs RVMDW Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, RVMDW has a market cap of 37.1B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while RVMDW trades at $9.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas RVMDW's P/E ratio is -1.07. In terms of profitability, ARQT's ROE is +0.15%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, ARQT is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check RVMDW's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
ARQT vs ALNY Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, ALNY has a market cap of 30B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while ALNY trades at $232.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas ALNY's P/E ratio is 40.46. In terms of profitability, ARQT's ROE is +0.15%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, ARQT is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
ARQT vs ROIV Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, ROIV has a market cap of 24.7B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while ROIV trades at $35.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas ROIV's P/E ratio is -32.55. In terms of profitability, ARQT's ROE is +0.15%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, ARQT is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ROIV's competition here
BioNTech SE (NASDAQ: BNTX)
ARQT vs BNTX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, BNTX has a market cap of 23.1B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while BNTX trades at $96.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas BNTX's P/E ratio is -11.94. In terms of profitability, ARQT's ROE is +0.15%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, ARQT is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check BNTX's competition here
Incyte Corporation (NASDAQ: INCY)
ARQT vs INCY Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, INCY has a market cap of 22.9B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while INCY trades at $112.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas INCY's P/E ratio is 15.15. In terms of profitability, ARQT's ROE is +0.15%, compared to INCY's ROE of +0.30%. Regarding short-term risk, ARQT is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
ARQT vs UTHR Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, UTHR has a market cap of 22.6B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while UTHR trades at $549.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas UTHR's P/E ratio is 19.06. In terms of profitability, ARQT's ROE is +0.15%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, ARQT is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
ARQT vs GMAB Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, GMAB has a market cap of 22.1B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while GMAB trades at $37.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas GMAB's P/E ratio is 27.17. In terms of profitability, ARQT's ROE is +0.15%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, ARQT is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check GMAB's competition here
Insmed Incorporated (NASDAQ: INSM)
ARQT vs INSM Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, INSM has a market cap of 21.8B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while INSM trades at $100.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas INSM's P/E ratio is -24.45. In terms of profitability, ARQT's ROE is +0.15%, compared to INSM's ROE of -1.11%. Regarding short-term risk, ARQT is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
ARQT vs BGNE Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas BGNE's P/E ratio is -22.55. In terms of profitability, ARQT's ROE is +0.15%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, ARQT is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
ARQT vs DNA-WT Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, ARQT's ROE is +0.15%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, ARQT is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
ARQT vs EXEL Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, EXEL has a market cap of 14.8B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while EXEL trades at $59.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas EXEL's P/E ratio is 16.86. In terms of profitability, ARQT's ROE is +0.15%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, ARQT is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check EXEL's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
ARQT vs NBIX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, NBIX has a market cap of 14.2B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while NBIX trades at $142.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas NBIX's P/E ratio is 20.41. In terms of profitability, ARQT's ROE is +0.15%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, ARQT is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
ARQT vs JAZZ Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, JAZZ has a market cap of 14B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while JAZZ trades at $218.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas JAZZ's P/E ratio is 8.29. In terms of profitability, ARQT's ROE is +0.15%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, ARQT is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
ARQT vs ASND Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, ASND has a market cap of 13.8B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while ASND trades at $229.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas ASND's P/E ratio is -92.02. In terms of profitability, ARQT's ROE is +0.15%, compared to ASND's ROE of +1.90%. Regarding short-term risk, ARQT is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ASND's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
ARQT vs SMMT Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, SMMT has a market cap of 13.7B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while SMMT trades at $17.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas SMMT's P/E ratio is -15.33. In terms of profitability, ARQT's ROE is +0.15%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, ARQT is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
ARQT vs HALO Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, HALO has a market cap of 13B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while HALO trades at $110.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas HALO's P/E ratio is 20.49. In terms of profitability, ARQT's ROE is +0.15%, compared to HALO's ROE of +1.81%. Regarding short-term risk, ARQT is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check HALO's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
ARQT vs BBIO Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, BBIO has a market cap of 12.7B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while BBIO trades at $65.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas BBIO's P/E ratio is -17.39. In terms of profitability, ARQT's ROE is +0.15%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, ARQT is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
ARQT vs KRTX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas KRTX's P/E ratio is -28.09. In terms of profitability, ARQT's ROE is +0.15%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, ARQT is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check KRTX's competition here
Bio-Techne Corporation (NASDAQ: TECH)
ARQT vs TECH Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while TECH trades at $72.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas TECH's P/E ratio is 37.35. In terms of profitability, ARQT's ROE is +0.15%, compared to TECH's ROE of +0.09%. Regarding short-term risk, ARQT is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
ARQT vs RNAM Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas RNAM's P/E ratio is -17.39. In terms of profitability, ARQT's ROE is +0.15%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, ARQT is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check RNAM's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
ARQT vs MDGL Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, MDGL has a market cap of 11B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while MDGL trades at $471.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas MDGL's P/E ratio is -37.26. In terms of profitability, ARQT's ROE is +0.15%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, ARQT is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check MDGL's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
ARQT vs BMRN Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while BMRN trades at $54.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas BMRN's P/E ratio is 26.39. In terms of profitability, ARQT's ROE is +0.15%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, ARQT is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check BMRN's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
ARQT vs IBRX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, IBRX has a market cap of 10.4B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while IBRX trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas IBRX's P/E ratio is -10.22. In terms of profitability, ARQT's ROE is +0.15%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, ARQT is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check IBRX's competition here
10x Genomics, Inc. (NASDAQ: TXG)
ARQT vs TXG Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, TXG has a market cap of 9.8B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while TXG trades at $80.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas TXG's P/E ratio is -130.98. In terms of profitability, ARQT's ROE is +0.15%, compared to TXG's ROE of -0.09%. Regarding short-term risk, ARQT is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check TXG's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
ARQT vs KRYS Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, KRYS has a market cap of 9.6B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while KRYS trades at $331.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas KRYS's P/E ratio is 41.02. In terms of profitability, ARQT's ROE is +0.15%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, ARQT is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
ARQT vs RXDX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas RXDX's P/E ratio is -56.47. In terms of profitability, ARQT's ROE is +0.15%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, ARQT is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check RXDX's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
ARQT vs TWST Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, TWST has a market cap of 9.5B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while TWST trades at $159.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas TWST's P/E ratio is -68.49. In terms of profitability, ARQT's ROE is +0.15%, compared to TWST's ROE of -0.30%. Regarding short-term risk, ARQT is less volatile compared to TWST. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check TWST's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
ARQT vs PCVX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, PCVX has a market cap of 9.4B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while PCVX trades at $71.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas PCVX's P/E ratio is -8.52. In terms of profitability, ARQT's ROE is +0.15%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, ARQT is less volatile compared to PCVX. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check PCVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
ARQT vs NUVL Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas NUVL's P/E ratio is -21.79. In terms of profitability, ARQT's ROE is +0.15%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, ARQT is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
ARQT vs CRNX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas CRNX's P/E ratio is -16.86. In terms of profitability, ARQT's ROE is +0.15%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, ARQT is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
ARQT vs PTGX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, PTGX has a market cap of 9B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while PTGX trades at $143.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas PTGX's P/E ratio is 135.83. In terms of profitability, ARQT's ROE is +0.15%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, ARQT is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check PTGX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
ARQT vs KYMR Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, KYMR has a market cap of 9B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while KYMR trades at $112.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas KYMR's P/E ratio is -34.16. In terms of profitability, ARQT's ROE is +0.15%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, ARQT is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check KYMR's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
ARQT vs AXSM Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, AXSM has a market cap of 8.8B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while AXSM trades at $168.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas AXSM's P/E ratio is -44.41. In terms of profitability, ARQT's ROE is +0.15%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, ARQT is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check AXSM's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
ARQT vs IMGN Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas IMGN's P/E ratio is -111.55. In terms of profitability, ARQT's ROE is +0.15%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, ARQT is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check IMGN's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
ARQT vs ARWR Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, ARWR has a market cap of 8.6B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while ARWR trades at $62.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas ARWR's P/E ratio is -27.00. In terms of profitability, ARQT's ROE is +0.15%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, ARQT is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ARWR's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
ARQT vs APGE Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas APGE's P/E ratio is -31.19. In terms of profitability, ARQT's ROE is +0.15%, compared to APGE's ROE of -0.30%. Regarding short-term risk, ARQT is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
ARQT vs BPMC Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas BPMC's P/E ratio is -51.58. In terms of profitability, ARQT's ROE is +0.15%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, ARQT is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check BPMC's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
ARQT vs CERE Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas CERE's P/E ratio is -16.47. In terms of profitability, ARQT's ROE is +0.15%, compared to CERE's ROE of -0.72%. Regarding short-term risk, ARQT is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CERE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
ARQT vs TGTX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, TGTX has a market cap of 8.2B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while TGTX trades at $55.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas TGTX's P/E ratio is 19.33. In terms of profitability, ARQT's ROE is +0.15%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, ARQT is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check TGTX's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
ARQT vs CAI Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, CAI has a market cap of 7.8B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while CAI trades at $29.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas CAI's P/E ratio is 77.27. In terms of profitability, ARQT's ROE is +0.15%, compared to CAI's ROE of +0.19%. Regarding short-term risk, ARQT is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CAI's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
ARQT vs CYTK Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, CYTK has a market cap of 7.7B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while CYTK trades at $62.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas CYTK's P/E ratio is -8.59. In terms of profitability, ARQT's ROE is +0.15%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, ARQT is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CYTK's competition here
Metsera, Inc. (NASDAQ: MTSR)
ARQT vs MTSR Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas MTSR's P/E ratio is -23.58. In terms of profitability, ARQT's ROE is +0.15%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, ARQT is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check MTSR's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
ARQT vs PRAX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, PRAX has a market cap of 7.3B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while PRAX trades at $259.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas PRAX's P/E ratio is -20.38. In terms of profitability, ARQT's ROE is +0.15%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, ARQT is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check PRAX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
ARQT vs IONS Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, IONS has a market cap of 7.2B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while IONS trades at $45.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas IONS's P/E ratio is -13.24. In terms of profitability, ARQT's ROE is +0.15%, compared to IONS's ROE of -1.11%. Regarding short-term risk, ARQT is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check IONS's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
ARQT vs SYRE Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, SYRE has a market cap of 6.9B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while SYRE trades at $85.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas SYRE's P/E ratio is -40.97. In terms of profitability, ARQT's ROE is +0.15%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, ARQT is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check SYRE's competition here
Merus N.V. (NASDAQ: MRUS)
ARQT vs MRUS Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas MRUS's P/E ratio is -17.05. In terms of profitability, ARQT's ROE is +0.15%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, ARQT is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
ARQT vs ACLX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas ACLX's P/E ratio is -28.27. In terms of profitability, ARQT's ROE is +0.15%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, ARQT is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
ARQT vs RETA Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas RETA's P/E ratio is -66.29. In terms of profitability, ARQT's ROE is +0.15%, compared to RETA's ROE of +0.47%. Regarding short-term risk, ARQT is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check RETA's competition here
Abivax S.A. (NASDAQ: ABVX)
ARQT vs ABVX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, ABVX has a market cap of 6.5B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while ABVX trades at $88.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas ABVX's P/E ratio is -14.59. In terms of profitability, ARQT's ROE is +0.15%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, ARQT is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ABVX's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
ARQT vs CNTA Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas CNTA's P/E ratio is -22.63. In terms of profitability, ARQT's ROE is +0.15%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, ARQT is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CNTA's competition here
Immunovant, Inc. (NASDAQ: IMVT)
ARQT vs IMVT Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, IMVT has a market cap of 6.2B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while IMVT trades at $30.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas IMVT's P/E ratio is -10.73. In terms of profitability, ARQT's ROE is +0.15%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, ARQT is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check IMVT's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
ARQT vs RYTM Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, RYTM has a market cap of 6.1B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while RYTM trades at $90.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas RYTM's P/E ratio is -28.82. In terms of profitability, ARQT's ROE is +0.15%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, ARQT is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check RYTM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
ARQT vs BLTE Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while BLTE trades at $154.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas BLTE's P/E ratio is -81.56. In terms of profitability, ARQT's ROE is +0.15%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, ARQT is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check BLTE's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
ARQT vs IOVA Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, IOVA has a market cap of 5.9B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while IOVA trades at $14.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas IOVA's P/E ratio is -18.23. In terms of profitability, ARQT's ROE is +0.15%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, ARQT is less volatile compared to IOVA. This indicates lower risk in terms of short-term price fluctuations for ARQT.Check IOVA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
ARQT vs LGND Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, LGND has a market cap of 5.9B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while LGND trades at $301.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas LGND's P/E ratio is 32.38. In terms of profitability, ARQT's ROE is +0.15%, compared to LGND's ROE of +0.20%. Regarding short-term risk, ARQT is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check LGND's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
ARQT vs KOD Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, KOD has a market cap of 5.9B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while KOD trades at $99.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas KOD's P/E ratio is -22.60. In terms of profitability, ARQT's ROE is +0.15%, compared to KOD's ROE of -2.73%. Regarding short-term risk, ARQT is more volatile compared to KOD. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check KOD's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
ARQT vs CDTX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas CDTX's P/E ratio is -19.77. In terms of profitability, ARQT's ROE is +0.15%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, ARQT is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CDTX's competition here
CG Oncology Inc. (NASDAQ: CGON)
ARQT vs CGON Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, CGON has a market cap of 5.6B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while CGON trades at $63.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas CGON's P/E ratio is -23.52. In terms of profitability, ARQT's ROE is +0.15%, compared to CGON's ROE of -0.25%. Regarding short-term risk, ARQT is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CGON's competition here
Abcam plc (NASDAQ: ABCM)
ARQT vs ABCM Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, ARQT's ROE is +0.15%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, ARQT is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
ARQT vs ISEE Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas ISEE's P/E ratio is -22.44. In terms of profitability, ARQT's ROE is +0.15%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, ARQT is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ISEE's competition here
Erasca, Inc. (NASDAQ: ERAS)
ARQT vs ERAS Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, ERAS has a market cap of 5.4B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while ERAS trades at $16.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas ERAS's P/E ratio is -16.62. In terms of profitability, ARQT's ROE is +0.15%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, ARQT is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ERAS's competition here
Veradermics, Incorporated (NYSE: MANE)
ARQT vs MANE Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, MANE has a market cap of 5.3B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while MANE trades at $130.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas MANE's P/E ratio is -40.34. In terms of profitability, ARQT's ROE is +0.15%, compared to MANE's ROE of -0.38%. Regarding short-term risk, ARQT is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check MANE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
ARQT vs APLS Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas APLS's P/E ratio is 38.35. In terms of profitability, ARQT's ROE is +0.15%, compared to APLS's ROE of +0.40%. Regarding short-term risk, ARQT is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check APLS's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
ARQT vs PTCT Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, PTCT has a market cap of 5.2B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while PTCT trades at $64.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas PTCT's P/E ratio is -26.85. In terms of profitability, ARQT's ROE is +0.15%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, ARQT is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check PTCT's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
ARQT vs COGT Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, COGT has a market cap of 5.1B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while COGT trades at $31.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas COGT's P/E ratio is -14.26. In terms of profitability, ARQT's ROE is +0.15%, compared to COGT's ROE of -0.73%. Regarding short-term risk, ARQT is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check COGT's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
ARQT vs SRRK Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, SRRK has a market cap of 5.1B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while SRRK trades at $42.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas SRRK's P/E ratio is -12.23. In terms of profitability, ARQT's ROE is +0.15%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, ARQT is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check SRRK's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
ARQT vs MIRM Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, MIRM has a market cap of 5B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while MIRM trades at $86.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas MIRM's P/E ratio is -5.59. In terms of profitability, ARQT's ROE is +0.15%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, ARQT is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check MIRM's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
ARQT vs CRSP Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while CRSP trades at $53.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas CRSP's P/E ratio is -10.60. In terms of profitability, ARQT's ROE is +0.15%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, ARQT is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CRSP's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
ARQT vs TVTX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, TVTX has a market cap of 4.8B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while TVTX trades at $52.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas TVTX's P/E ratio is -115.64. In terms of profitability, ARQT's ROE is +0.15%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, ARQT is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check TVTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
ARQT vs TERN Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas TERN's P/E ratio is -51.41. In terms of profitability, ARQT's ROE is +0.15%, compared to TERN's ROE of -0.14%. Regarding short-term risk, ARQT is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check TERN's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
ARQT vs ORKA Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, ORKA has a market cap of 4.7B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while ORKA trades at $82.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas ORKA's P/E ratio is -39.84. In terms of profitability, ARQT's ROE is +0.15%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, ARQT is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ORKA's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
ARQT vs DNTH Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, DNTH has a market cap of 4.6B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while DNTH trades at $82.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas DNTH's P/E ratio is -19.86. In terms of profitability, ARQT's ROE is +0.15%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, ARQT is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check DNTH's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
ARQT vs FOLD Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas FOLD's P/E ratio is -161.00. In terms of profitability, ARQT's ROE is +0.15%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, ARQT is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check FOLD's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
ARQT vs DFTX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, DFTX has a market cap of 4.5B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while DFTX trades at $36.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas DFTX's P/E ratio is N/A. In terms of profitability, ARQT's ROE is +0.15%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, ARQT is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check DFTX's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
ARQT vs AKRO Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas AKRO's P/E ratio is -14.57. In terms of profitability, ARQT's ROE is +0.15%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, ARQT is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
ARQT vs ALPN Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas ALPN's P/E ratio is -101.52. In terms of profitability, ARQT's ROE is +0.15%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, ARQT is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ALPN's competition here
Opthea Limited (NASDAQ: OPT)
ARQT vs OPT Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas OPT's P/E ratio is -1.52. In terms of profitability, ARQT's ROE is +0.15%, compared to OPT's ROE of +1.18%. Regarding short-term risk, ARQT is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
ARQT vs PRTC Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas PRTC's P/E ratio is -3.78. In terms of profitability, ARQT's ROE is +0.15%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, ARQT is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check PRTC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
ARQT vs EWTX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, EWTX has a market cap of 4.2B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while EWTX trades at $39.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas EWTX's P/E ratio is -21.21. In terms of profitability, ARQT's ROE is +0.15%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, ARQT is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check EWTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
ARQT vs ADPT Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, ADPT has a market cap of 4.2B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while ADPT trades at $26.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas ADPT's P/E ratio is -63.63. In terms of profitability, ARQT's ROE is +0.15%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, ARQT is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ADPT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
ARQT vs MRTX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas MRTX's P/E ratio is -4.82. In terms of profitability, ARQT's ROE is +0.15%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, ARQT is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check MRTX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
ARQT vs CPRX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas CPRX's P/E ratio is 17.49. In terms of profitability, ARQT's ROE is +0.15%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, ARQT is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CPRX's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
ARQT vs RLAY Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, RLAY has a market cap of 3.8B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while RLAY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas RLAY's P/E ratio is -11.09. In terms of profitability, ARQT's ROE is +0.15%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, ARQT is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check RLAY's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
ARQT vs RYZB Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas RYZB's P/E ratio is -57.86. In terms of profitability, ARQT's ROE is +0.15%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, ARQT is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check RYZB's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
ARQT vs TLX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, TLX has a market cap of 3.7B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while TLX trades at $11.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas TLX's P/E ratio is 114.93. In terms of profitability, ARQT's ROE is +0.15%, compared to TLX's ROE of +0.07%. Regarding short-term risk, ARQT is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check TLX's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
ARQT vs CBAY Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas CBAY's P/E ratio is -32.81. In terms of profitability, ARQT's ROE is +0.15%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, ARQT is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check CBAY's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
ARQT vs TNGX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, TNGX has a market cap of 3.7B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while TNGX trades at $23.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas TNGX's P/E ratio is -27.19. In terms of profitability, ARQT's ROE is +0.15%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, ARQT is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check TNGX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
ARQT vs ABCL Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, ABCL has a market cap of 3.7B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while ABCL trades at $12.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas ABCL's P/E ratio is -22.26. In terms of profitability, ARQT's ROE is +0.15%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, ARQT is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check ABCL's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
ARQT vs SWTX Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas SWTX's P/E ratio is -13.78. In terms of profitability, ARQT's ROE is +0.15%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, ARQT is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check SWTX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
ARQT vs XENE Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, XENE has a market cap of 3.5B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while XENE trades at $36.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas XENE's P/E ratio is -7.69. In terms of profitability, ARQT's ROE is +0.15%, compared to XENE's ROE of -0.44%. Regarding short-term risk, ARQT is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check XENE's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
ARQT vs LEGN Comparison October 2026
Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, ARQT stands at 3.1B. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, ARQT is priced at $26.58 on the NASDAQ, while LEGN trades at $18.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
ARQT currently has a P/E ratio of 116.62, whereas LEGN's P/E ratio is -27.51. In terms of profitability, ARQT's ROE is +0.15%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, ARQT is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for ARQT.Check LEGN's competition here